Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee

Nat Rev Drug Discov. 2014 May;13(5):395-7. doi: 10.1038/nrd3713-c1. Epub 2014 Apr 22.

Authors

Peter Arlett¹, Geraldine Portier¹, Roberto de Lisa¹, Kevin Blake¹, Noel Wathion¹, Jean-Michel Dogne², Almath Spooner³, June Raine⁴, Guido Rasi¹

Affiliations

¹ European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E14 4 HB, UK.
² Federal Agency for Medicines and Health Products, Victor Horta Place, 40/40, 1060 Brussels, Belgium.
³ Irish Medicines Board, Earlsfort Terrace Dublin 2, Ireland.
⁴ Medicines and Healthcare products Regulatory Agency, 151 Buckingham Palace Road, London SW1W 9SZ, UK.

PMID: 24751815
DOI: 10.1038/nrd3713-c1

No abstract available

Publication types

Letter

MeSH terms

Drug and Narcotic Control / legislation & jurisprudence*
Drug and Narcotic Control / methods
European Union
Humans
Pharmacovigilance*
Product Surveillance, Postmarketing*
Risk Assessment